Zio ECG Utilization Software (ZEUS) System vs Cardiomo
AI Verdict
Choose Zio ECG Utilization Software (ZEUS) System if…
Choose Zio ECG Utilization Software (ZEUS) System if you are a healthcare professional seeking a comprehensive, FDA-cleared, cloud-based platform for long-term continuous ECG data analysis (up to 14 days) to diagnose and manage cardiac arrhythmias in adult patients. It is particularly well-suited for streamlining clinical workflows, accessing detailed end-of-wear reports, and integrating with existing EHR systems for efficient patient management.
View Zio ECG Utilization Software (ZEUS) System →Choose Cardiomo if…
Choose Cardiomo if you are looking for a medical-grade wearable device and AI-powered platform for continuous and remote heart health monitoring, especially for individuals who may benefit from real-time alerts to users and caregivers regarding potential cardiovascular events or falls. This tool is ideal for ongoing monitoring of vital signs like ECG, heart rate, respiration, and skin temperature, with a focus on timely notifications and a long battery life for user convenience.
View Cardiomo →For physicians evaluating AI-powered cardiac monitoring solutions, the Zio ECG Utilization Software (ZEUS) System and Cardiomo offer distinct approaches. ZEUS, from iRhythm Technologies, is a cloud-based platform specifically designed to analyze continuous ECG data from proprietary Zio wearable monitors. Its strength lies in comprehensive, deep-learned algorithmic analysis of up to 14 days of ECG data, providing detailed end-of-wear reports to aid in the diagnosis and management of cardiac arrhythmias. This makes ZEUS particularly well-suited for cardiologists and internal medicine physicians focused on in-depth diagnostic review of extended ECG recordings.
In contrast, Cardiomo provides a medical-grade wearable device paired with an AI platform for continuous vital sign monitoring, including ECG, heart rate, respiration, and skin temperature. Its key differentiator is real-time alerting for detected cardiovascular events and fall detection, making it more geared towards proactive monitoring and timely intervention. The practical difference lies in their primary focus: ZEUS excels at retrospective, detailed diagnostic analysis over an extended period, while Cardiomo prioritizes continuous, real-time alerting for immediate concerns. Physicians seeking a robust diagnostic tool for arrhythmia characterization over several days would likely prefer ZEUS. Conversely, those prioritizing continuous, real-time vital sign monitoring with immediate alerts for at-risk patients, potentially in geriatrics or for general cardiovascular health, might find Cardiomo more aligned with their needs.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Zio ECG Utilization Software (ZEUS) System | Cardiomo |
|---|---|---|
| Pricing | Contact for pricing | Contact for pricing |
| Deployment | Cloud-based (AWS EC2 platform) | Cloud-based with wearable device and mobile app |
| FDA Status | Yes AI-estimated | Unknown |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Zio ECG Utilization Software (ZEUS) SystemTool A (ZEUS System) emphasizes an end-to-end service with a focus on patient compliance (99%) through its small, light, and thin Zio monitor, and a user-friendly clinician portal (ZioSuite web portal and mobile app) for streamlined workflows and report interpretation. Tool B (Cardiomo) also highlights ease of use with its wearable patch and mobile app, but lacks specific metrics on patient or clinician adherence.
Clinical Value
Zio ECG Utilization Software (ZEUS) SystemTool A (ZEUS System) has FDA clearance and CE Mark for its AI algorithm and monitoring system, with reports demonstrating 99% physician agreement and improved diagnostic yield compared to traditional Holter monitoring. Tool B (Cardiomo) states it is medical-grade and ISO 13485 certified, and has undergone pilot projects and clinical validation, but specific FDA clearance for its core AI disease detection and real-time alerts is not clearly stated as obtained, only applied for.
Pricing & Value
TieBoth Tool A (ZEUS System) and Tool B (Cardiomo) require contacting them directly for current pricing, making a direct comparison of value difficult. While Cardiomo previously offered a public price, it is no longer current. Both aim to provide long-term monitoring, which generally offers better value than short-term solutions.
Enterprise Readiness
Zio ECG Utilization Software (ZEUS) SystemTool A (ZEUS System) demonstrates stronger enterprise readiness with HL7-based EHR integration, a comprehensive web portal (ZioSuite) for healthcare professionals, and a clear focus on streamlining clinical workflows. Tool B (Cardiomo) mentions HIPAA-compliant cloud analytics and real-time alerts for caregivers, but its enterprise integration capabilities are less explicitly detailed.
Innovation
Zio ECG Utilization Software (ZEUS) SystemTool A (ZEUS System) leverages proprietary deep-learned algorithms for enhanced diagnostic accuracy and has received FDA clearance for its AI system, including for use with the Zio Watch in partnership with Verily. Tool B (Cardiomo) also uses AI for disease detection and real-time alerts, and offers continuous vital sign monitoring, but Tool A's established regulatory clearances and partnerships suggest a more validated and integrated innovative approach in the clinical setting.
Support & Docs
Zio ECG Utilization Software (ZEUS) SystemTool A (ZEUS System) provides readily available Instructions for Use (IFU) in multiple languages for both patients and healthcare professionals, indicating a robust documentation and support structure. While Tool B (Cardiomo) mentions a user manual is available upon request, the public accessibility and breadth of support documentation are not as evident.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Zio ECG Utilization Software (ZEUS) System | Cardiomo |
|---|---|---|
| Company | iRhythm Technologies | Cardiomo, Inc. |
| Key Features (Monitoring/Detection) | AI algorithm for arrhythmia detection and classification, Continuous ECG data analysis (up to 14 days) | Continuous vital sign monitoring (ECG, heart rate, respiration, skin temperature), AI-powered disease detection (arrhythmias, cardiovascular events), Fall detection |
| Key Features (Reporting/Access) | ZioSuite web portal and mobile application for healthcare professionals, Comprehensive end-of-wear reports for physician review, HL7-based EHR integration | Real-time alerts and notifications, Mobile application (Android and iOS) |
| Specialties | Cardiology, Family Medicine, Internal Medicine | Cardiology, Geriatrics, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Zio ECG Utilization Software (ZEUS) System and Cardiomo.
Frequently Asked Questions
More Comparisons
More matchups featuring Zio ECG Utilization Software (ZEUS) System or Cardiomo
Backers
Who funded each tool's parent company.